{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:16:35Z","timestamp":1761844595121,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,15]],"date-time":"2017-01-15T00:00:00Z","timestamp":1484438400000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"DMK","award":["AI 057552"],"award-info":[{"award-number":["AI 057552"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.virol.2015.10.033","type":"journal-article","created":{"date-parts":[[2015,11,21]],"date-time":"2015-11-21T20:15:23Z","timestamp":1448136923000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus"],"prefix":"10.1016","volume":"488","author":[{"given":"Fernando M.","family":"Diaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Knipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2015.10.033_bib1","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1128\/JVI.00849-11","volume":"85","author":"Awasthi","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.033_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157016212800618156","article-title":"Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions","volume":"10","author":"Barnabas","year":"2012","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.virol.2015.10.033_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2015.10.033_bib4","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1128\/JVI.00374-12","article-title":"Identification of a divalent metal cation binding site in herpes simplex virus 1 (HSV-1) ICP8 required for HSV replication","volume":"86","author":"Bryant","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.033_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00350-08","article-title":"Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay","volume":"16","author":"Burbelo","year":"2009","journal-title":"Clin. Vacc. Immunol."},{"key":"10.1016\/j.virol.2015.10.033_bib6","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1073\/pnas.86.12.4736","article-title":"Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate","volume":"86","author":"Coen","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2015.10.033_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.virol.2013.12.014","article-title":"Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain","volume":"450\u2013451","author":"Colgrove","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.virol.2015.10.033_bib8","first-page":"331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group","volume":"28","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.virol.2015.10.033_bib9","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1128\/JVI.74.17.7963-7971.2000","article-title":"Construction, phenotypic analysis, and immunogenicity of a UL5\/UL29 double deletion mutant of herpes simplex virus 2","volume":"74","author":"Da Costa","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.033_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1997.8564","article-title":"Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital herpes","volume":"232","author":"Da Costa","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.virol.2015.10.033_bib11","doi-asserted-by":"crossref","first-page":"e46714","DOI":"10.1371\/journal.pone.0046714","article-title":"Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model","volume":"7","author":"Delagrave","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2015.10.033_bib12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1586\/erv.12.129","article-title":"The challenge of developing a herpes simplex virus 2 vaccine","volume":"11","author":"Dropulic","year":"2012","journal-title":"Expert Rev. Vacc."},{"key":"10.1016\/j.virol.2015.10.033_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2007.10.014","article-title":"Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes","volume":"372","author":"Dudek","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.virol.2015.10.033_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/infdis\/jir047","article-title":"Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa","volume":"203","author":"Dudek","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2015.10.033_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.virol.2015.10.033_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.virol.2012.10.006","article-title":"Varicella zoster vaccines and their implications for development of HSV vaccines","volume":"435","author":"Gershon","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.virol.2015.10.033_bib17","first-page":"374","article-title":"Immunization Against Viral Diseases","volume":"1","author":"Graham","year":"2013"},{"key":"10.1016\/j.virol.2015.10.033_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/JVI.79.1.410-418.2005","article-title":"Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs","volume":"79","author":"Hoshino","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.033_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1086\/605645","article-title":"Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs","volume":"200","author":"Hoshino","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2015.10.033_bib20","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1016\/j.vaccine.2008.05.022","article-title":"Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs","volume":"26","author":"Hoshino","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2015.10.033_bib21","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1172\/JCI57148","article-title":"HSV-2: In pursuit of a vaccine","volume":"121","author":"Johnston","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2015.10.033_bib22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.vaccine.2013.08.066","article-title":"Current status and prospects for development of an HSV vaccine","volume":"32","author":"Johnston","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2015.10.033_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/viro.2000.0628","article-title":"Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model","volume":"278","author":"Jones","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.virol.2015.10.033_bib24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.vaccine.2014.01.052","article-title":"Summary and recommendations from a national institute of allergy and infectious diseases (NIAID) workshop on \"next generation herpes simplex virus vaccines","volume":"32","author":"Knipe","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2015.10.033_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nprot.2006.461","article-title":"Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity","volume":"2","author":"Malin","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.virol.2015.10.033_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/viro.1998.9047","article-title":"Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge","volume":"243","author":"Morrison","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.virol.2015.10.033_bib27","first-page":"369","article-title":"A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2","volume":"70","author":"Parr","year":"1994","journal-title":"Lab. Invest."},{"key":"10.1016\/j.virol.2015.10.033_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/14728214.13.1.41","article-title":"The potential impact of a prophylactic herpes simplex vaccine","volume":"13","author":"Rupp","year":"2008","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.virol.2015.10.033_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/iai.34.3.684-692.1981","article-title":"Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4","volume":"34","author":"Showalter","year":"1981","journal-title":"Infect. Immun."},{"key":"10.1016\/j.virol.2015.10.033_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/jvi.45.1.332-342.1983","article-title":"Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein","volume":"45","author":"Spang","year":"1983","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2015.10.033_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/infdis\/146.3.397","article-title":"Genital herpes in guinea pigs: Pathogenesis of the primary infection and description of recurrent disease","volume":"146","author":"Stanberry","year":"1982","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2015.10.033_bib32","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2015.10.033_bib33","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1086\/514103","article-title":"Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial","volume":"176","author":"Straus","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2015.10.033_bib34","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1016\/j.vaccine.2012.09.057","article-title":"A vaxfectin((R))-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes","volume":"30","author":"Veselenak","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2015.10.033_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0042-6822(76)90151-3","article-title":"A new method for the isolation of herpes simplex virus type 2 DNA","volume":"74","author":"Walboomers","year":"1976","journal-title":"Virology"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682215004614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682215004614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:32:59Z","timestamp":1758587579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682215004614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":35,"alternative-id":["S0042682215004614"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2015.10.033","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2015.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}